Plastic surgery is a specialty that is now worldwide recognized as its own academic discipline within the surgical community. The roots however are as old as 600 BC when in the Sushruta Ayurveda the reconstruction of a nose with a flap from the forehead was described. Plastic surgery is a problem solving discipline that meanwhile is an integral part within modern surgical concepts. A number of groundbreaking inventions and developments from plastic surgery had led to relevant innovations and these influenced the whole field of surgical specialities, including the nobel prize for the first successful renal transplantation, performed by the plastic surgeon John Murray. Although principal details of operation techniques that had been described as early as 600 BC are still part of the surgical armamentarium, many innovative methods have enriched the current spectrum of possibilities. Whereas over many centuries techniques of reconstruction utilized delayed pedicled random pattern flaps and needed multi stage procedures (even before the advent of anaesthesia) today axially vascularized and perforator based flaps have replaced these often tedious and painful techniques. It was the publication of the Indian method of nose reconstruction in the Gentlemen´s magazine in England that replaced the random pattern flap based method that was described in Tagliacozzi's two volume book De Curtorum Chirurgia per Insitionem (1597), where he detailed the different surgical steps with graphic illustrations that became a hallmark of surgical textbooks ever since.
When within the last decades the rapid development of microsurgery allowed for transplantation of vascularized tissue to almost any part of the body this spread as a fascinating extension of older surgical methods to many other surgical specialities as well. Modern reconstructive and oncological concepts rely on the interdisciplinary character of plastic surgery making our specialty an essential part of any reconstructive concept and rendering plastic surgery as a problem solving discipline within the concert of all medical specialities. It has been shown that such modern interdisciplinary concepts contribute significantly to improving the patient´s quality of life.
As an example one can look at the salvage of hypovascularized wounds in the lower extremity, that is made possible by transferring well vascularized tissue utilizing microsurgery. This concept utilizes the surgical induction of angiogenesis for the treatment of chronic, poorly vascularized wounds, such as in diabetic ulcers and ulcers following arteriosclerotic disease [1] [2] [3] [4] [5] . Autologous venous bypass grafts can be used as a prolongation or as arterio-venous loops to allow for a distal free flap connection even in the absence of appropriate local vessels, before amputation is necessitated. We have been using this concept for more than 20 years now and have investigated a larger cohort of such selected patients who needed bypasses and microsurgical free flaps. We have therefore assessed and advocated an algorithm based on our results and from current literature data [6] [7] [8] [9] [10] [11] .
Perforator flaps have significantly contributed to a further reduction in donor sit morbidity when compared to myocutaneous or muscle flaps. Perforator flaps have been advocated to be another soft tissue choice for all zones of the lower extremity, recognizing that donor site function preservation is their major asset because in such perforator flaps no muscle needs to be included [ Figures 1 and 2 ]. When patients do not have relevant microperfusion problems in the recipient area and when arterial inflow is not compromised, peninsular, propellor, or advancement perforator flaps can be regarded as valuable local non-microsurgical flap alternatives in appropriate cases [12] . However, the indication to decide whether a local flap or a free tissue transfer is necessary depends on the localization and the size of the defect as well as on the vascular situation of the recipient site [13] . In diabetic foot ulcers for instance the indications for local flaps are rather limited. It also has to be taken into account that any local flap does not only cause a donor site defect but also may further deteriorate the vascular supply of the distal extremity. In experimental studies the potential role of neo-angiogenesis at the non-ischemic/ ischemic interfaces are key to the biological healing process. Such interfaces occur after transfer of free vascularized flaps into ischemic wounds [14, 15] . Due to the standardization of microsurgery the age of patients seems to be no hindrance to become eligible for free flap transfers to the lower extremity. A correlation between flap loss and increased risk factors and age was not found in the elderly population so far [16] [17] [18] .
We have gained experience with more than 100 patients who received a bypass or an av-loop (primarily or staged) along with a free flap and we could show that weighed against the gain in quality of life the donor site morbidity is comparatively low and acceptable. Nevertheless a consequent patient selection and a thorough planning can help to keep the rate of complications low.
It is the daily routine of plastic surgeons to deal with tissue loss and tissue replacement. Therefore it is of no wonder that plastic surgeons who were engaged in replacing lost tissue were amongst the initial founders of what has then be termed tissue engineering (TE) and hence have been involved into all kinds of research in TE and regenerative medicine. Basically the initial idea of TE was to build appropriate scaffolds and then seed cells on such matrices to transplant them into the recipient area. In the laboratory considerable results have been obtained in generating replacement tissue but have not found their way into daily clinical practice yet. The main obstacle has turned out to be the lack of initial vascularization especially in large constructs [19] . These suffer from sufficient initial blood supply after transplantation to nourish inherent or adherent cells right from the beginning of their inset. One possible way to overcome this problem is the prevascularization of such scaffolds utilizing microsurgically created arterio-venous (av-) loops to three-dimensionally vascularize large constructs before the designated cells are inoculated [ Figure 3 ]. These prevascularized constructs can then be successfully transplanted [20] [21] [22] [23] .
Methods derived from such approaches have been successfully implemented into the clinical scenario [24] [25] [26] [27] . For the first time in the literature we were able to successfully apply av-loops in two patients, fill in the patient´s own bone marrow stem cells, along with a hydroxyl-apatite powder and fibrin sealant and we then have seen a permanent replacement and restoration of large human bone defects [28] . This is a very promising approach that offers a way from bench to bedside already in selected cases. Latest advances now include the integration of 3D bioprinting of cells and proteins together with biodegradable matrices [ Figures 4 and 5] , generally now perceived as the new field of "biofabrication" [29] . It has been postulated by researchers that bioprinting would now be on the cusp of entering the translational phase where laboratory research practices can be scaled up into manufacturing products specifically designed for individual patients [30] . In addition to tissue replacement such modalities could help to also fight systemic conditions, such as diabetes mellitus or malignant diseases. With the help of biofabricated protein synthesizing producer cells in a 3D microvascularly connected defined container it can become possible to treat systemic or local diseaeses. The advantage of such containers with 3D hierarchically printed reporter/producer cells would be that it could potentially produce antibodies in a clinically relevant amount and could be removed when no longer needed. Ravnic et al. [31] reported on recent successful attempts to generate beta-cells and how this can be coupled with bioprinting technologies in order to fabricate pancreas tissues, which holds great potential for type 1 diabetes. They postulated that it would be possible to integrate vascularization and encapsulation in bioprinted tissues. This would lend other future prospects, such as pancreas-on-a-chip or organoids on a chip [31] . Our own group is actively investigating the value of bioprinting to generate such arterialized 3D prevascularized containers which can then be loaded with protein producing cells. These cells are supposed to continuously express functional substances and address specific functions in the recipient organism. This interdisciplinary approach is a fine example of how we can combine the knowledge, skills and expertise of plastic surgical microvascular techniques with the science of bioengineering and biology. Therefore, it seems promising to help our patients better than today with customized solutions to overcome morbidities that are rarely curable today. In summary, all the findings from regenerative medicine and tissue engineering are now more and more merging into the new field of biofabrication. This might well enrich our daily clinical practice of to the benefit of our patients by combining the art of plastic surgery with basic science [32, 33] .
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